Insect sting allergy and venom immunotherapy (Q36404340)

14 August 2017

1 reference

title

Insect sting allergy and venom immunotherapy (English)

1 reference

14 August 2017

0 references

1 reference

1 reference

1 reference

0 references

David B K Golden

1

1 reference

PubMed ID

16496507

14 August 2017

language of work or name

1 reference

1 February 2006

1 reference

Annals of Allergy, Asthma & Immunology

14 August 2017

1 reference

14 August 2017

96

1 reference

14 August 2017

2 Suppl 1

1 reference

14 August 2017

S16-21

1 reference

Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Insect sting allergy with negative venom skin test responses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

A controlled trial of immunotherapy in insect hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Natural history of large local reactions from stinging insects.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

A prospective study of the natural history of large local reactions after Hymenoptera stings in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

The value of immunotherapy with venom in children with allergy to insect stings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Outcomes of allergy to insect stings in children, with and without venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Regimens of Hymenoptera venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Long-term efficacy of preseasonal grass pollen immunotherapy in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Long-term clinical efficacy of grass-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Survey of patients after discontinuing venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Stinging insect hypersensitivity: a practice parameter update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Role of interleukin 10 in specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Discontinuing venom immunotherapy: outcome after five years.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Discontinuing venom immunotherapy: extended observations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Clinical and immunologic follow-up of patients who stop venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Discontinuation of bee venom immunotherapy in children and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960897-6

7 January 2021

10.1016/S1081-1206(10)60897-6

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16496507